Acorda Therapeutics (ACOR - Get Report)
Ampyra net revenue in the first quarter totaled $112 million, short of the $121 million consensus

Alexion Pharmaceuticals (ALXN - Get Report)
First-quarter adjusted EPS of $1.38 topped consensus of $1.24 with total revenue of $870 million

Astrazeneca (AZN - Get Report)
Results of its closely watched cancer immunotherapy study should be released by "mid-2017"

Bristol-Myers Squibb (BMY - Get Report)
Opdivo sales of $1.13 billion topped consensus of $1.03 billion

Alkermes (ALKS - Get Report)
Revenue of $192 million missed a consensus of $196 million

Celgene (CELG - Get Report)

Revlimid sales of $1.88 billion were essentially in line with consensus of $1.87 billion

Read Full Article: Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

This article was written by a staff member of TheStreet.